WebFDA Calendar. Our FDA Calendar is designed to provide you with future catalysts across biotech & pharma companies, updated on a daily basis for all companies we cover. … WebApr 1, 2024 · Our Biotech Stock Watch List is our go to newsletter for key upcoming catalysts. Biotech stock catalysts include upcoming clinical data readouts and regulatory decisions (e.g. PDUFA dates) for a combination of small and large cap biotech stocks listed on NYSE and NASDAQ. This is delivered once per week on Saturdays at 11am ET, and …
PDUFA Date Calendar for Biotech Stocks • BioPharmCatalyst
WebApr 10, 2024 · U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment. 3/29/2024. Today, Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved NARCAN® … WebApr 12, 2024 · 4/5/2024. Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today that its development partner Newsoara Biopharma Co. Ltd, has enrolled the first patient in its ongoing Phase 3 clinical trial in China. popit toys walmart
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
WebOur enhanced FDA calendar integrates PDUFA dates, clinical trial primary completion dates, and working capital runway estimates into a single timeline that covers all companies facing upcoming PDUFA dates. Streamline your research and quickly compare the … COVID-19 clinical trial primary completion dates, PDUFA dates, and working … FDA Tracker. Analytics for Pharma and Biotech Traders. Membership Levels. … Burn Rate is a screening tool that estimates cash runways for biotech/pharma … User guides for our products are available here: Trial Tracker; Burn Rate; … FDA Tracker was established in 2011 to help pharma and biotech traders … FDA Tracker. Analytics for Pharma and Biotech Traders. Contact. We will … Analytics for Pharma and Biotech Traders. FDA Tracker Blog. Trials. March 1, … WebApr 10, 2024 · The biotech — which is set to become part of Amgen once its $28.3 billion deal goes through — targeted thyroid eye disease patients with low ... FDA sets adcomm dates for Sarepta, Pfizer ... WebOct 1, 2024 · The FDA was set to decide on approval by August, too, but extended its review to go over two-year results that BioMarin submitted from a Phase 3 trial. Those results have shown that treatment with vosoritide led to greater gains in height than a placebo in year two, and position BioMarin well for a positive decision. shares to buy in usa